Tyra Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by Tyra Biosciences, Inc. on May 28, 2026. The filing details the outcomes of shareholder votes regarding director elections and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
No material financial changes are reported in this filing. The primary events are the successful election of three Class II directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural report of voting results.
Key Facts for Investors
- Director Elections: Three Class II directors were elected for a three-year term expiring in 2029: Habib J. Dable, Susan Moran, M.D., M.S.C.E., and Robert More.
- Voting Results: Robert More received the highest number of withheld votes (3,705,719) compared to his colleagues, though he was still elected.
- Auditor Ratification: Shareholders overwhelmingly ratified the appointment of Ernst & Young LLP, with 53,092,820 votes for and only 1,316 against.
- Broker Non-Votes: There were 8,377,977 broker non-votes recorded for the director elections.